By Aakash B
March 20 (Reuters) - The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc's treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
The decision is a big win for the drugmaker whose patents covering its blockbuster narcolepsy drug, Xyrem, was declared invalid by a U.S. appeals court in July. (Reporting by Aakash Jagadeesh Babu and Supriya Roy in Bengaluru; Editing by Richard Chang)